A polyurethane vascular access graft and a hybrid polytetrafluoroethylene graft as an arteriovenous fistula for hemodialysis: Comparison with an expanded polytetrafluoroethylene graft

被引:15
作者
Matsuda, H
Miyazaki, M
Oka, Y
Nakao, A
Choda, Y
Kokumai, Y
Kunitomo, K
Tanaka, N
机构
[1] Okayama Univ, Div Abdominal Transplant, Dept Surg, Dept Surg 1,Grad Sch Med & Dent, Okayama 7008558, Japan
[2] Okayama Saiwaicho Mem Hosp, Dept Surg, Okayama, Japan
关键词
polyurethane graft; hybrid polytetrafluoroethylene graft; expanded polytetrafluoroethylene graft; graft patency; blood access; hemodialysis;
D O I
10.1046/j.1525-1594.2003.07031.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Aim: We evaluated a polyurethane vascular access graft (TVAG), a hybrid polytetrafluoroethylene graft (hPTFEG), and an expanded polytetrafluoroethylene graft (ePTFEG) for postoperative complications and graft patency in their use as prosthetic devices of vascular access for hemodialysis. Methods: Between August 1993 and October 2001, we treated 200 patients in whom A-V fistulas were placed by the same surgeon. These were divided into the following four groups according to the type of blood access: 27 cases of ePTFEG, 23 cases of TVAG, 22 cases of hPTFEG, and 128 cases of an autogenous A-V fistula. We calculated the cumulative patency rates by the Kaplan-Meier method, including primary (problem-free) and secondary (revised or functional) patency rates. Results: The hPTFEG group experienced few thromboses. The absence of perigraft edema in the TVAG group permitted the early use of the TVAG within a few postoperative days for hemodialysis. Among the three graft groups, the primary patency was the best in the hPTFEG group (94.7% at 1 year and 86.1% at 2 years), with a significant difference versus the ePTFEG group. In regard to secondary patency, hPTFEG had an excellent patency of 100% at 1 year and 90.9% at 2 years, and TVAG had a comparable patency with that of ePTFEG. Conclusion: The hPTFEG was considered superior to ePTFEG in terms of being complication-free and had the excellent 2 year secondary patency of 90.9%. TVAG, with a patency equal to that of ePTFEG, could be used immediately after implantation due to the absence of limb edema.
引用
收藏
页码:722 / 727
页数:6
相关论文
共 7 条
  • [1] Australian multicentre evaluation of a new polyurethane vascular access graft
    Allen, RDM
    Yuill, E
    Nankivell, BJ
    Francis, DMA
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1996, 66 (11): : 738 - 742
  • [2] Hofstra L, 1995, J AM SOC NEPHROL, V6, P1625
  • [3] Matsuda H., 1999, J JPN SURG ASS, V60, P915
  • [4] Nakao A, 2000, ACTA MED OKAYAMA, V54, P91
  • [5] Report on the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996
    Shinzato, T
    Nakai, S
    Akiba, T
    Yamagami, S
    Yamazaki, C
    Kitaoka, T
    Kubo, K
    Maeda, K
    Morii, H
    [J]. KIDNEY INTERNATIONAL, 1999, 55 (02) : 700 - 712
  • [6] CURRENT STATUS OF RENAL REPLACEMENT THERAPY IN JAPAN
    TERAOKA, S
    TOMA, H
    NIHEI, H
    OTA, K
    BABAZONO, T
    ISHIKAWA, I
    SHINODA, A
    MAEDA, K
    KOSHIKAWA, S
    TAKAHASHI, T
    SONODA, T
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (01) : 151 - 164
  • [7] Tordoir J H, 1988, Eur J Vasc Surg, V2, P3, DOI 10.1016/S0950-821X(88)80099-9